Oncology Knowledge Into Practice offentlig
[search 0]
Mer
Download the App!
show episodes
 
In this bi-weekly podcast, cancer experts discuss game-changing topics in clinical oncology. Produced by Oncology Knowledge into Practice (www.onckip.com), this podcast will support and inform your practice in cancer management. This podcast is intended for healthcare professionals only. Funding information is available in each episode's notes. Access more free education today! Visit the OncKIP website, follow us on Twitter (@onckip ) or connect on LinkedIn. https://www.oncologyknowledgeinto ...
  continue reading
 
Loading …
show series
 
In today's episode, we welcome Dr. Sandip Patel, who is a Professor of Medical Oncology at the University of California, San Diego, to discuss the evolution of molecular profiling technology, focusing on how next-generation sequencing can help support patients with advanced thyroid cancer, but also how to integrate molecular profiling into clinical…
  continue reading
 
In today's episode, we welcome Dr. Conor Steuer, which is Associate Professor at the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, USA, to discuss adaptation of thyroid cancer guidelines to local care settings. We touch on strategies for guideline implementation and how to overcome potential barrie…
  continue reading
 
Developments in precision medicine have led to a paradigm shift in the management of advanced thyroid cancer. The ESMO Guidelines Committee recently developed a new clinical practice guideline on the use of systemic therapy in this setting. This episode offers guideline insights into the applications recently approved therapies that have been appro…
  continue reading
 
In today’s episode, we welcome expert Oncologist Dr. Claire Arthur and expert Endocrinologist Dr. Sarimar Agosto Salgado to discuss the challenges they have encountered and strategies that they have implemented to improve multidisciplinary collaboration in the management of patients with thyroid cancer and continued integration of precision medicin…
  continue reading
 
In today’s episode, we welcome Dr. Antonio Matrone, an endocrinologist at the University of Pisa, to discuss the many factors involved in treatment decision-making and strategies for the management of patients with advanced thyroid cancer where an oncogenic driver has been identified. References Matrone A et al. Differentiated thyroid cancer, from …
  continue reading
 
In today’s episode, we welcome Principal Researcher Dr. David Tamborero who was integral to the development of the Molecular Tumor Board Portal to discuss the benefits associated with molecular tumor boards and the way in which the portal can support the discussions that take place at tumor board meetings, as well as how these initiatives can suppo…
  continue reading
 
In today’s episode, we welcome expert Oncologist Dr. Lori Wirth and expert Pathologist Dr. Thomas Giordano to discuss the challenges they have encountered and strategies that they have implemented to improve multidisciplinary collaboration in the management of patients with thyroid cancer and continued integration of precision medicine approaches. …
  continue reading
 
Liquid biopsy has emerged as a novel diagnostic tool, enabling rapid, non-invasive molecular testing of thyroid cancers. This episode offers insight into some of the opportunities and challenges that are presented by liquid biopsy in this field. To answer questions on this topic, we have invited Professor Frederique Penault-Llorca to join us. She i…
  continue reading
 
Developments in RET-targeted therapies have led to a paradigm shift in the management of advanced thyroid cancer. However, resistance to these drugs has been observed to develop through a variety of mechanisms, so precise monitoring is required to detect and react to disease development. This episode offers insight into relevant mechanisms of resis…
  continue reading
 
Rearranged during transfection (RET) and tropomyosin receptor kinase (TRK) fusions are involved in various adult and paediatric cancers, including thyroid cancers. There is a high mortality rate for some of these cancers, partly due to the lack of efficient detection, diagnosis, and prognosis. The US and European guidelines recommend genomic testin…
  continue reading
 
In today’s episode, we’re going to talk about how precision medicine fits into thyroid cancer treatment guidelines. To answer our questions on this topic, we welcome the expertise of Dr. Lori Wirth. Dr. Wirth is Medical Director of the Center for Head and Neck Cancers at the Massachusetts General Hospital, and an Associate Professor in Medicine at …
  continue reading
 
Precision medicine is a promising field that’s opening doors to novel therapeutics for many patients. But how does it fit into thyroid cancer specifically? What treatments are available or in the pipeline, for which patient subgroup, and what are the potential benefits? We’ll start off our series by exploring these questions, and we’ve invited Dr E…
  continue reading
 
In this episode we speak with Dr Navel Daver, Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA, to get his thoughts on the highlights of ASCO and EHA for patients with MDS and AML. Funding Statement: This series is supported by educational grants from Servier Pharmaceuticals LLC and Takeda, who hav…
  continue reading
 
At the ASCO and EHA conferences, there were many interesting posters and presentations in the field of haemato-oncology. To share their conference highlights, we’ve invited our ALL expert Dr Dieter Hoelzer, director of internal medicine at the University of Frankfurt in Germany, and our MDS and AML expert Dr Amer Zeidan, Associate Professor Of Inte…
  continue reading
 
Adult guidelines for acute myeloid leukaemia recommend determining a patient’s fitness before treating with standard therapy, but what does this mean, what are the implications, and how does this work in practice for both adults and children? To answer our questions on this topic, we’ve invited the expertise of Dr Courtney DiNardo, Associate Profes…
  continue reading
 
Despite available treatments, many patients with acute myeloid leukaemia, or AML, are in need of additional therapeutic options. Thankfully, there hundreds of clinical trials for new interventions that could rectify this, but which options can we start to consider, for which patients and when? To answer our questions on this topic, we’ve invited th…
  continue reading
 
Although most commonly a disease of the old, Acute Myeloid Leukaemia is also a significant burden for younger patients, but it can present in different ways and they should not be treated equal. So how should younger and older patients be classified and treated? To help answer some of our questions on this topic is Dr. Tapan Kadia, Associate Profes…
  continue reading
 
For patients with myelodysplastic syndrome, or MDS, their therapy options vary considerably depending on their prognosis and risk of developing AML. Today we discuss risk stratification systems and their rationale, and consider their utility in clinical practice. To answer our questions on this topic, we welcome Professor Detlaf Haase, medical dire…
  continue reading
 
Last week we discussed the array of therapeutic options in the pipeline for patients with MDS. Today we shine a spotlight on NAE inhibitors, the first of which recently received FDA breakthrough designation to bring it to the clinic faster. To answer our questions about the current data and future therapeutic use for this novel class of drugs, we w…
  continue reading
 
Despite available treatments, there is still an unmet need to improve outcomes for some patients with myelodysplastic syndrome, or MDS. Thankfully, there is a wide array of therapies in development that could fill this gap, but which therapies can we start to consider as real future options for which patients? To answer our questions on this topic,…
  continue reading
 
Myelodysplastic syndrome, or MDS is a rare blood disorder that often develops into acute myeloid leukaemia. Guideline recommendations can support treatment decisions for these patients, but some questions remain about best practice. In today’s episode, we’ve invited Dr Platzbecker, clinical director in the Hematology and Cellular Therapy department…
  continue reading
 
Asparaginase is an important component of effective treatment strategies for adolescent and young adult patients with acute lymphoblastic leukaemia, but its associated adverse events must be effectively managed. To discuss this, we welcome Dr Dieter Hoelzer, Director of Internal Medicine and ALL specialist at the University of Frankfurt in Germany.…
  continue reading
 
Adolescent and young adult patients with acute lymphoblastic leukaemia have been shown to benefit from paediatric inspired treatment regimens, however these regimens present unique challenges when it comes to adverse-event management. Today we’ve invited Dr Patrick Brown, Director of the Paediatric Leukaemia Programme at Johns Hopkins Medicine, Bal…
  continue reading
 
In our second episode on ALL we’ll be looking at adolescent and young adult (AYA) patients. Although these patients are commonly seen in the adult setting, evidence suggests that paediatric-inspired regimens may improve their outcomes. But how should these be implemented practically? Joining us this week is Dr Emily Curran, Assistant Professor in t…
  continue reading
 
To start off our mini-series on ALL, this episode we’ll be looking at adolescent and young adult (AYA) patients. Although these patients are commonly seen in the adult setting, evidence suggests that pediatric-inspired regimens may improve their outcomes. But how should these be implemented practically? Joining us this week is Dr Adam DuVall, Assis…
  continue reading
 
Although breast cancer was once considered a “non-immunogenic” cancer, numerous studies demonstrate PD-L1 expression in the breast cancer micro-environment, and now several immune checkpoint inhibitors are under investigation in this patient group. To help us to interpret the results of all of these trials and to begin thinking about how this class…
  continue reading
 
Immune checkpoint inhibitors are a relatively new treatment option for patients with metastatic, unresectable head and neck squamous cell carcinoma (HNSCC), and so they have not yet been incorporated into clinical practice guidelines. For this reason, we interview Professor Frederic Peyrade, Head of Clinical Research and Professor of Oncology, Anto…
  continue reading
 
Several immune checkpoint inhibitors have indications in non small-cell lung cancer (NSCLC), but it is not always easy to decide which patients to treat when, and with which regimen. In today’s episode, we’ve invited Professor Martin Reck from the Lung Clinic Grosshansdorf in Germany to answer some of our questions about best practice when consider…
  continue reading
 
Histological specimens are recommended to assess a patient’s PD-L1 status; however, it is not always easy or even feasible to secure a histological specimen in advanced cancers such as stage IV NSCLC. Cytological specimens are typically used in this setting to assess other molecular markers such as ALK or ROS1 – should they also be used to assess P…
  continue reading
 
PD-L1 status has long been explored as a predictive biomarker for immune checkpoint inhibitors. However, the clinical evidence for its efficacy has been mixed, so how should PD-L1 status be used in clinical practice? In the first episode in this series on immuno-oncology, Dr Vaibhav Patel from the Icahn School of Medicine at Mount Sinai, New York, …
  continue reading
 
In this bi-weekly podcast, cancer experts discuss game-changing topics in clinical oncology. Produced by Oncology Knowledge into Practice (www.onckip.com), this podcast series will support and inform your practice in cancer management. This podcast is intended for healthcare professionals only. Funding information is available in each episode's not…
  continue reading
 
Loading …

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett